Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data

Johannes Clouth (), Astra M. Liepa (), Guido Moeser (), Heiko Friedel (), Magdalena Bernzen (), Jörg Trojan () and Elena Garal-Pantaler ()
Additional contact information
Johannes Clouth: Medical Affairs, Lilly Deutschland GmbH
Astra M. Liepa: Eli Lilly and Company, Lilly Corporate Center
Guido Moeser: masem Research Institute GmbH
Heiko Friedel: Team Gesundheit GmbH
Magdalena Bernzen: Team Gesundheit GmbH
Jörg Trojan: Universitätsklinikum Frankfurt
Elena Garal-Pantaler: Team Gesundheit GmbH

Health Economics Review, 2018, vol. 8, issue 1, 1-10

Abstract: Abstract Objective To estimate both the number of patients with hepatocellular carcinoma (HCC) eligible annually for second-line therapy following sorafenib in Germany and the healthcare costs accrued by patients meeting eligibility criteria. Methods Patients with an HCC diagnosis and one or more sorafenib prescription were identified from samples of > 3 million insured persons in each of 2012, 2013 and 2014 using the anonymised Betriebskrankenkasse health insurance scheme database. Incidence rates from 2013 were extrapolated to the German population using data from the statutory health insurance system database and Robert Koch Institute. Resource use and cost data were collected for a subset of patients with follow-up data post-sorafenib. Results Between 1032 and 1484 patients with HCC in Germany (893–1390 publicly insured patients) were estimated as likely to be eligible for second-line therapy after sorafenib annually. For post-sorafenib analyses, 117 patients were identified with HCC, one or more sorafenib prescription and considered potentially eligible for second-line treatment, 15 of whom were alive after 12 months’ follow-up. Total mean costs per patient accrued in the 12 months after sorafenib treatment ended were €11,152 (hospital care, €6483 [58.1%]; outpatient prescriptions, €3137 [28.1%]). Conclusion The estimated number of publicly insured HCC patients annually eligible for second-line therapy in Germany was

Keywords: Hepatocellular carcinoma; Germany; Second line; Sorafenib; Health economics; German statutory health insurance claims data (search for similar items in EconPapers)
Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1186/s13561-018-0199-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:8:y:2018:i:1:d:10.1186_s13561-018-0199-1

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/s13561-018-0199-1

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().